- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01467583
Fondaparinux in Critically Ill Patients With Renal Failure
Use of Fondaparinux in Critically Ill Patients With Renal Failure
Study Overview
Detailed Description
We will be studying fondaparinux 2.5 mg subcutaneously every 48 hr in three distinct patient groups: 1) Acute kidney failure without hemodialysis, 2) Acute kidney failure (AKI) with intermittent hemodialysis (IHD) and 3) Acute renal failure with continuous renal replacement therapy (CRRT). All patients will be assessed for efficacy of the dose. Efficacy will be assessed by following clinically for any evidence of VTE, either deep venous thrombosis (DVT) or pulmonary embolism. In addition, lower extremity duplex studies will be performed at baseline and at the end of the study period to assess for DVT.
Secondary objectives will be safety and accumulation. Safety will be determined by assessment of clinically significant bleeding, defined as a drop in Hgb of > 2 grams (gm) in 24 hr, or the need for red blood cell transfusion related to bleeding. Accumulation may occur in renal failure and will be studied throughout the intensive care unit (ICU) stay through reevaluation of levels over time.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Detroit Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years old and ≤ 89 years old
- Body weight ≥ 50 kg or ≤ 150 kg
- Estimated creatinine clearance of < 30 mL/min
- Predicted ICU stay of more than 72 hours.
Exclusion Criteria:
- Pregnant women
- Infective Endocarditis
- Neuraxial anesthesia or spinal puncture
- Active bleeding
- Treatment with vitamin K antagonists or therapeutic doses of unfractionated heparin
- Signs of disseminated intravascular coagulation
- Severe liver failure (serum bilirubin > 5 mg/dL)
- Surgery planned within 24 hours of ICU admission
- Latex allergy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Renal failure on intermittent dialysis
These are patients with renal failure, on intermittent hemodialysis (IHD), receiving fondaparinux 2.5 mg subcutaneously every 48 hours
|
2.5 mg every 48 hours
Other Names:
|
Experimental: Renal failure-renal replacement therapy
These are patients with renal failure, either acute or chronic, on continuous renal replacement therapy (CRRT) receiving fondaparinux 2.5 mg subcutaneously every 48 hours
|
2.5 mg every 48 hours
Other Names:
|
Experimental: Renal failure, not on dialysis
These are patients with acute kidney injury not yet on dialysis, receiving fondaparinux 2.5 mg subcutaneously every 48 hours
|
2.5 mg every 48 hours
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To Determine if an Adjusted-dose of Fondaparinux 2.5 mg Subcutaneously (SQ) q48 hr in Critically Ill Patients With Renal Failure Will Achieve Peak and Trough Levels Similar to Patients With Normal Renal Function on 2.5 mg SQ Daily Dosing of Fondaparinux.
Time Frame: 2 years
|
Fondaparinux Peak Levels measured at time +3 hours after the dose, and Trough Levels, measured at time + 47 hours post-dose around the first 5 doses of fondaparinux and then every 3rd dose thereafter.
Levels will be sent to our hospital laboratory and performed using a calibrated fondaparinux assay.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To Determine Number of Participants Who Experienced a Bleeding Event, Either Major or Minor, and to Determine the Number of Participants Who Experienced a Venous Thromboembolism During the Study Period
Time Frame: 2 years
|
Safety will be assessed through monitoring for clinical signs of bleeding.
Major and minor bleeding will be documented.
In additions, venous doppler studies of the bilateral lower extremities will be performed at study entry and study completion to monitor for any evidence of venous thromboembolism during the study period.
We will report on the number of participants experiencing an adverse event during the study
|
2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Steven D Tennenberg, MD, WSU, DMC
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Kidney Diseases
- Urologic Diseases
- Disease Attributes
- Embolism and Thrombosis
- Renal Insufficiency
- Critical Illness
- Thromboembolism
- Venous Thromboembolism
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Protease Inhibitors
- Factor Xa Inhibitors
- Antithrombins
- Serine Proteinase Inhibitors
- Anticoagulants
- Fondaparinux
- PENTA
Other Study ID Numbers
- 112050
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Venous Thromboembolism
-
BayerWithdrawnTotal Hip Replacement | Total Knee Replacement | Prophylaxis, Thromboembolism, Venous
-
University Hospital, BrestRecruitingVenous Thromboembolism (VTE)France
-
University of ArizonaRecruitingPediatric Venous ThromboembolismUnited States
-
National Taiwan University HospitalUnknownDeep Venous ThromboembolismTaiwan
-
Ya-Wei XuFirst Affiliated Hospital, Sun Yat-Sen University; Nanfang Hospital of Southern...RecruitingVenous Thromboembolism (VTE)China
-
Bristol-Myers SquibbCompletedVenous Thromboembolism (VTE)United States
-
BayerCompletedTreatment of Venous ThromboembolismJapan
-
Azidus BrasilUnknownPrevention of Venous ThromboembolismBrazil
-
Fadoi Foundation, ItalyCompletedPrevention of Venous ThromboembolismItaly
-
Fadoi Foundation, ItalyUniversity Of PerugiaCompletedPrevention of Venous ThromboembolismItaly
Clinical Trials on Fondaparinux
-
GlaxoSmithKlineCompletedAcute Coronary SyndromeCanada, France, Bulgaria, Germany, Poland, United Kingdom, Spain, Russian Federation, Korea, Republic of, Netherlands, India, United States, Brazil, Hungary, Italy, Argentina, Czech Republic, Greece
-
GlaxoSmithKlineSanofiCompleted
-
University of Veterinary and Animal Sciences, Lahore...Not yet recruitingPolycystic Ovary Syndrome | Metabolic Syndrome
-
Children's Hospital of PhiladelphiaWithdrawn
-
GlaxoSmithKlineCompletedThromboembolism | Venous ThromboembolismGermany
-
Università degli Studi dell'InsubriaTerminatedRenal Insufficiency | Medical PatientsItaly
-
Duke UniversityGlaxoSmithKlineWithdrawnKidney DiseasesUnited States
-
Indiana University School of MedicineAmerican Society for Bariatric SurgeryWithdrawn
-
NYU Langone HealthGlaxoSmithKlineWithdrawn